Clinical trials: Thoracic Cancer
Lung Cancer
Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound
All patients undergoing video-assisted thoracoscopic (VATS) resection of lung cancer will receive standard therapy including lobectomy or sub-lobar resection and mediastinal lymph node dissection.
- Trial name
- NCT02218242
- Testing
- Intraoperative ultrasound
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Joel Thompson, PhD
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Trial name
- NCT04214262
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 390 sites in United States
- Volunteers
- 417 people
- Sponsor
- National Cancer Institute (NCI)
Lung Neoplasms
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the…
- Trial name
- NCT01466660
- Testing
- Afatinib, gefitinib
- Where
- 63 sites in Australia, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Boehringer Ingelheim
Lung Neoplasms, Lung Cancer
Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients
The proposed study is in the field of thoracic radiation oncology where radiation therapy is used to treat lung cancer. The primary objective of the early phase clinical trial will be to evaluate the safety of performing…
- Trial name
- NCT02528942
- Testing
- Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Colorado, Denver
NSCLC (Non-small Cell Lung Carcinoma)
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is…
- Trial name
- NCT02119650
- Testing
- Ruxolitinib, Pemetrexed, Cisplatin
- Where
- 30 sites in United States
- Volunteers
- 76 people
- Sponsor
- Incyte Corporation
Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either.
- Trial name
- NCT00949910
- Testing
- Erlotinib
- Where
- 543 sites in Albania, Argentina and 49 more
- Volunteers
- 6,586 people
- Sponsor
- Hoffmann-La Roche
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT00334815
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 61 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
Primary Objective: To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen.
- Trial name
- NCT00410189
- Testing
- ZD6474
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Non-Small Cell
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer.
- Trial name
- PEARL (NCT01853878)
- Testing
- Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
- Where
- 39 sites in United States, Estonia and 7 more
- Volunteers
- 137 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Non-Small Cell
Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery
Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.
- Trial name
- NCT00290355
- Testing
- GSK 249553 vaccine
- Where
- 62 sites in Belgium, Estonia and 12 more
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.
- Trial name
- NCT02388074
- Testing
- CyPath®
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- bioAffinity Technologies Inc.
Non-small Cell Lung Cancer
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
- Trial name
- NCT00063154
- Testing
- Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
- Trial name
- NCT03840902
- Testing
- M7824, Durvalumab, Etoposide
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 153 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Colorectal Cancer, Non-small Cell Lung Cancer
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed population of patients with specified solid tumors
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Renal Cell Carcinoma
- Trial name
- NCT03576131
- Testing
- GEN1029 (HexaBody®-DR5/DR5)
- Where
- 6 sites in United States, Spain and 1 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Lung Cancer
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in…
- Trial name
- NCT03322566
- Testing
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 233 people
- Sponsor
- Incyte Corporation
Lung Neoplasm Malignant
Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer
The investigators will evaluate the feasibility of implementing a low-intensity, patient-centered activity regimen (PCAR) that prioritizes education and communication over a 12-week period in advanced stage lung cancer patients.
- Trial name
- NCT03352245
- Testing
- Prescribed Activity
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
The study designed is to evaluate the safety of Canady Helios™ Cold Plasma Scalpel (CHCPS) in patients with solid tumors with carcinomatosis scheduled to undergo surgical resection for cytoreduction.
- Conditions
- Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT04267575
- Testing
- Canady Helios Cold Plasma Scalpel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jerome Canady, M.D.
Non-small Cell Lung Cancer
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT00530621
- Testing
- enzastaurin, pemetrexed
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor…
- Trial name
- NCT00661193
- Testing
- carboplatin, erlotinib hydrochloride, paclitaxel
- Where
- 124 sites in United States
- Volunteers
- 59 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.